Commentary
Video
Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma
Author(s):
Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.
Wojciech Jurczak, MD, PhD, Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, discusses findings from the phase 2 BELLWAVE-003 study (NCT04728893) of nemtabrutinib in relapsed or refractory follicular lymphoma. These findings were presented at the 2024 ASH Annual Meeting.
Related Videos
Related Content
